Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Gilead is en­list­ing a new part­ner in the bustling field of an­ti­body-drug con­ju­gates, a type of chemother­a­py that it’s strug­gled to cap­i­tal­ize on since buy­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER